Gastroesophageal Cancer Clinical Trials

Screening

UCI 16-77 Identification of Features Associated with Dysplasia Using the NvisionVLE Imaging System Pilot Trial (Chang)

UCI 16-99 Multi-center Study to Evaluate the C2 CryoBalloon Focal Ablation System for the Treatment of Patients with Previously-Untreated Dysplastic Barrett’s Esophagus (Chang)

Stage IV/Advanced

ECOG-EAY131 Molecular Analysis for Therapy Choice (MATCH) (Bota)

SWOG S1609 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (Bota)

UCI 16-96 A Phase I Study of the Highly-Selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (Ou)

UCI 17-50** A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate in Subjects with Advanced Solid Tumor (Ou)

Correlative

UCI 16-88 Development of Esophageal and Gastric Cancer Patient Derived Xenograft Mouse Models to Investigate Chemotherapy Resistance and Tumor Cell Response (Lyou)

UCI 14-25 Plasma Exosome Concentration in Cancer Patients Undergoing Treatment (Nelson)

UCI 16-31 Importin α is a Novel Biomarker of Barrett’s Esophagus (BE)-Related Dysplasia & Cancer and Promotes Growth of BE-Derived Cancer Cells by Inducing Aberrant VEGF Expression (Samarasena)

For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu

**Opening soon